Saleh S, Turner P
Department of Clinical Pharmacology, St Bartholomew's Hospital, London.
Br J Clin Pharmacol. 1992 Sep;34(3):269-71. doi: 10.1111/j.1365-2125.1992.tb04136.x.
Medifoxamine is a novel monoamine re-uptake inhibiting antidepressive drug which preferentially inhibits dopamine reuptake. In human volunteer studies it has been found to reduce significantly intraocular pressure after single oral doses of 300-1000 mg, and to produce a small but statistically significant miosis. Its maximal ocular hypotensive action was less than that of oral timolol 20 mg.
美地沙明是一种新型单胺再摄取抑制性抗抑郁药物,它优先抑制多巴胺再摄取。在人体志愿者研究中发现,单次口服300 - 1000毫克后,它能显著降低眼压,并产生轻微但具有统计学意义的瞳孔缩小。其最大降眼压作用小于口服20毫克噻吗洛尔的作用。